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Synthesis and bioavailability of the endogenous gasomediator 
hydrogen sulfide (H2S) is perturbed in many disease states, 
including those involving mitochondrial dysfunction. There is 
intense interest in developing pharmacological agents to 
generate H2S. We have synthesised a novel H2S donor molecule 
coupled to a mitochondria-targeting moiety 
(triphenylphosphonium; TPP+) and compared the effectiveness 
of the compound against a standard non-TPP+ containing H2S 
donor (e.g. GYY4137) in the inhibition of oxidative stress- 
induced endothelial cell death. Our study suggests 
mitochondria-targeted H2S donors are useful pharmacological 
tools to study the mitochondrial physiology of H2S in health 
and disease. 
1  Introduction 
Hydrogen sulfide (H2S) is now convincingly established as 
the third gasotransmitter,1-3 alongside the more familiar nitric 
oxide (NO) and carbon monoxide (CO). It is enzymatically 
produced from amino acids cysteine, homocysteine and 
cystathionine by two pyridoxal-5'-phosphate-dependent 
enzymes, namely cystathionine-γ-lyase (CSE) and 
cystathionine-β-synthase (CBS).1-3 A third α-ketoglutarate and 
cysteine-dependent enzyme, located in the mitochondria of 
cells, 3-mercaptopyruvate sulfurtransferase (3-MST)4 has also 
been proposed to generate H2S within the mitochondria
5. 
In the vascular system, H2S has been proposed as an 
endothelium-derived vasodilator and genetic knock-out of CSE 
in animals results in hypertension6 and accelerates 
atherosclerosis7. Similarly, decreased H2S biosynthesis and/or 
bioavailability have been observed in various human disease 
states (and animal disease models)1-3 including those with 
marked mitochondrial and endothelial dysfunction and 
oxidative stress such as hypertension, diabetes, obesity8, pre-
eclampsia9 and after myocardial infarction10. Collectively, these 
studies have highlighted the therapeutic potential of 
pharmacological strategies to increase H2S bioavailability in 
these pathologies. 
 There is extensive evidence for a role of oxidative stress, 
and the over-production of detrimental oxidants, in the 
vascular endothelium of several human disease states 
including diabetes, obesity, hypertension and stroke11. 
Oxidant species such as peroxynitrite, (ONOO-) and 
hydrogen peroxide (H2O2), as well as the products of 
biomolecule oxidation such as the lipid-derived aldehyde 4-
hydroxynonenal (4-HNE), are well known to induce 
endothelial and mitochondrial dysfunction and cell death11.   
 Mitochondria are key intracellular organelles determining 
cell fate (survival and death) and they are a key source (and 
target) for detrimental oxidant production within cells12. As 
such, compounds that can ‘target’ mitochondria and prevent 
or limit mitochondria-mediated oxidative stress have 
received considerable attention and lipophilic cations such 
as triphenylphosphonium (TPP+) have been extensively used 
for this purpose13. TPP+ derivatives are extensively and 
rapidly taken up by mitochondria in vivo, due to the large 
negative membrane potential inside the mitochondria 
(∆ψm), resulting in the high concentration of the TPP+-
derivatives within the mitochondria13. The covalent 
attachment of the lipophilic TPP+ cation has become 
established as a generic and robust method for selectively 
delivering small, bioactive molecules to mitochondria in 
vivo.13 
H2S donor compounds such as GYY4137 1 (Fig. 1)
14 have 
been shown to exert prominent vasodilatory activity in vitro14,15 
and in hypertensive animals in vivo9,14,15. GYY4137 1 also 
inhibited inflammatory signalling in in vitro16-19 and in vivo 
models of sepsis18, arthritis20, pre-eclampsia9 and 
atherosclerosis21. Furthermore, GYY4137 has also been shown 
to inhibit oxidative stress-mediated cytotoxicity and loss of 
mitochondrial function induced by H2O2, ONOO
- and 4-HNE22. 
However, GYY4137 is highly water soluble14, limiting its 
cellular permeability, and the above studies have all used high 
concentrations of GYY4137 (≥100 µM) for anti-inflammatory, 
vasodilatory, cytoprotective and mitochondrial protective 
effects to be seen. The need for such high concentrations may 
further limit its therapeutic potential and alternative strategies 
for generating potent H2S donor molecules would be useful.  
Dithiolethiones, such as 2, have been proposed as novel 
species for H2S delivery (reviewed in
23) (Fig. 1) and 
dithiolethione derivatives of non-steroidal anti-inflammatory 
drugs (e.g. naproxen, diclofenac, indomethacin) have been 
clearly shown to generate H2S in vivo, promote gastro-intestinal 
blood flow and prevent gastric injury in vivo and exert 
prominent anti-inflammatory effects with marked additional 
pharmacological benefit over the parent NSAID alone23-28. 
 
 
Fig. 1 H2S donors; GYY4137 1, 5-(4-Hydroxyphenyl)-3H-
1,2-dithiole-3-thione 2. 
 
Therefore, with the above observations in mind, we have 
synthesised a TPP+-derivative of dithiolethione 2 to generate a 
novel mitochondria-targeted H2S donor molecule. We have then 
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evaluated its effects in a cellular model of oxidative stress and 
compared its efficacy with an established standard H2S donor, 
GYY4137 1. 
2  Results 
2.1 Synthesis 
 
 
 
Scheme 1 Preparation of AP39 3. Reagents and conditions: (a) 
triphenylphosphine (1.0 equiv.), CH3CN, reflux, 70 h; (b) 5-(4-
hydroxyphenyl)-3H-1,2-dithiole-3-thione 2 (1.0 equiv.), N,N-
dicyclohexylcarbodiimide (1.0 equiv.), 4-
dimethylaminopyridine (0.05 equiv.), CH2Cl2, room temp., 22 h 
(73% from 5). 
 
 
AP39 3 was prepared in an overall yield of 73% using the two-
step process shown in Scheme 1. Phosphonium salt 4 was 
prepared from 10-bromodecanoic acid 5 and 
triphenylphosphine under reflux conditions in acetonitrile33 and 
coupled, using standard carbodiimide conditions, to 5-(4-
hydroxyphenyl)-3H-1,2-dithiole-3-thione 2.26 Final purification 
of 3 was achieved using flash chromatography on silica gel 
(eluting with methanol), the product forming a crisp foam 
(which could be handled as a solid) on removal of the solvent. 
2.2  Intracellular generation of H2S from AP39 
Figure 2 show the generation of H2S from AP39 3, detected 
using two different fluorescence probes selective for sulfide, 
WSP-129,30 and 7-azido-4-methylcoumarin (AzMC)31,32. 
AP39 induced a concentration-dependent increase in WSP-1 
fluorescence, indicative of intracellular H2S generation
29 in 
human cerebral microvascular endothelial cells 
(hCMEC/D3) (Fig. 2A). Furthermore, exposure of B.End3 
cells to AP39 3 (100 nM) for 1 hour resulted in an increase 
in the fluorescence of an alternative H2S fluorophore AzMC, 
with significant co-localisation of the signal to mitochondria 
(Mitotracker) (Fig. 2B)  
2.3  Cytotoxicity 
Preliminary control experiments were conducted to confirm 
that the addition of up to 5 µM AP39 and 2 mM GYY4137 for 
24 h did not induce significant cytotoxicity compared with 
vehicle controls (alamarBlue®; data not shown). Figure 3 
shows concentration-dependent (7 – 250 nM) inhibition of 
oxidative stress-mediated toxicity in hCMEC/D3 cells by AP39 
3 and GYY4137 1 induced by [A] SIN-1 (500 µM), [B] H2O2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Intracellular generation of H2S from AP39. Endothelial cells were 
treated with 7-250 nM AP39 for 1 hour and intracellular H2S was detected in 
human hCMEC/D3 cells using WSP-1 [A]. Co-localisation of mitochondria and 
H2S was visualised after 1 hour treatment of murine B.End3 cells with AP39 (100 
nM) by fluorescence microscopy using MitoTracker Red (for mitochondria) and 
AzMC (for H2S) [B]. Images are representative images of three or more 
independent experiments. Note the concentration-dependent increase in H2S 
signal which, at least in part, co-localises within the mitochondrial regions 
suggesting AP39 generated H2S mainly in mitochondria.   
 
(50 µM) and [C] 4-HNE (10 µM). The concentration where 
50% of cell viability was recovered was estimated to be 25 
nM (vs SIN-1), 30 nM (vs H2O2) and >125 nM (vs 4-HNE). 
In order to show that the cytoprotective effects were due to 
AP39  3 and not the constituent parts of the AP39 molecule, 
cells were incubated with 100 nM of the H2S donor moiety 
(ADT-OH, 2), the phosphonium salt containing the 
mitochondria-targeting motif 4 individually and in 
combination, and then exposed the cells to SIN-1, H2O2 or 
4-HNE. Neither ADT-OH 2, compound 4 (TPP-decanoate) 
or a 100 nM each of ADT-OH 2 with 4, induced significant 
cytoprotection against oxidative stress-mediated 
cytotoxicity (Figs. 3A-C) confirming that cytoprotection 
was due to AP39 3. 
    We next compared the efficacy of AP39 3 against an 
established H2S donor compound GYY4137 1, which has 
previously been shown to protect human mesenchymal 
progenitor cells and articular chondrocytes from oxidative 
stress-mediated toxicity22. Figure 3 also shows that when used 
at the same concentration as AP39 (7 – 250nM), GYY4137 1 
was not cytoprotective. However, as expected14-20 significant 
inhibition of oxidative stress-induced cell death was observed 
with much higher concentrations (e.g. ≥100 µM) (Fig. 3D). 
From these studies, concentrations of 100 nM AP39 and 100 
µM GYY4137 1 were used for subsequent experiments.  
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Figure 3: Concentration-dependent inhibition of oxidative-stress induced cell 
death by AP39 and GYY4137. hCMEC/D3 cells were incubated with increasing 
concentrations of AP39 3 and GYY4137 1 (7-250 nM) for 1 hour and [A] SIN-1 
(500 µM), [B] H2O2 (50 µM) and [C] 4-HNE (10 µM) added. Higher 
concentrations of GYY4137 1 (10 – 500 µM) were also examined [D]. Control 
experiments were also performed using ADT-OH 2, compound 4, alone and in 
combination [A-C]. Cell viability was assessed by Alamar blue assay after 24 
hours.  *p<0.05, **p<0.01 and  *** p<0.001 H2S donors c.f. oxidant treatment 
 
 
2.4 Effects of H2S donors on mitochondrial membrane 
potential (∆Ψm), ATP and mitochondrial oxidant 
production 
 
Figure 4 shows AP39 3 (100 nM) and GYY4137 1 (100 µM) 
significantly inhibited oxidative stress-induced loss of 
mitochondrial membrane potential (Fig. 5A) and inhibited 
mitochondrial production of reactive oxygen species, detected 
using mitosox red (Fig. 4B). Incubation of cells with AP39 3 
(100 nM) or GYY417 1 (100 µM) alone had no significant 
effect on mitochondrial membrane potential or mitochondrial 
oxidant production (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Inhibition of oxidative-stress induced cell toxicity by H2S 
donors.  Human hCMEC/D3 endothelial cells were incubated with AP39 3 (100 
nM) or GYY4137 1 (100 µM) for 1 hour prior to the addition of SIN-1 (500 µM), 
H2O2 (50 µM) or 4-HNE (10 µM). After 24 hours, mitochondrial membrane 
potential [A] was determined using TMRM and mitochondrial oxidant production 
[B] determined using MitoSox. ###p<0.001 oxidant treated cells c.f. control; 
*p<0.05, ** p<0.01***, p<0.001 H2S donors c.f. oxidant treatment. 
 
Furthermore, AP39 (100 nM) significantly inhibited 
mitochondrial oxidant production induced by rotenone (5 µM), 
an inhibitor of mitochondrial respiratory complex I (Fig. 4A) 
and loss of ATP (Fig. 4B). GYY4137 also prevented rotenone-
induced mitochondrial toxicity, albeit when used at a final 
concentration of 100 µM. 
 
Figure 5: Inhibition of rotenone induced mitochondrial toxicity by H2S 
donors.  Human hCMEC/D3 endothelial cells were incubated with AP39 3 (100 
nM) or GYY4137 1 (100 µM) for 1 hour prior to the addition of rotenone (5 µM). 
Mitochondrial oxidant production was assessed using MitoSox (5 µM) [A] and 
ATP levels determined using firefly lantern luciferase [B]. ## p<0.01 and ### 
p<0.001 oxidant treated cells c.f. control; **p<0.01, *** p<0.001 H2S donors c.f. 
oxidant treatment 
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3  Experimental 
3.1  General synthetic chemistry methods 
Starting materials and reagents were obtained from 
commercial suppliers (Sigma-Aldrich and Fisher Scientific) 
and were used without further purification. Infrared spectra 
were recorded using a Perkin Elmer Spectrum BX FT-IR 
spectrometer. Only major absorbances are quoted, using the 
abbreviations: (for intensity) w, weak; m, medium; and s, 
strong. Samples were prepared as potassium bromide discs.    
1H NMR spectra were recorded at 300 MHz using a Bruker 
ACF300 spectrometer. Chemical shifts are quoted in ppm 
relative to tetramethylsilane, the residual solvent peak being 
used for referencing purposes. Coupling constants are 
quoted to the nearest 0.5 Hz with peak multiplicities for 
single resonances being labelled as: s, singlet; d, doublet; t, 
triplet; m, unresolved multiplet, AA'BB', AA'BB' pattern and 
br, broad. Where delineation of individual resonances is not 
possible, the relevant peaks are grouped together (over a 
chemical shift range) as complex. 
    31P NMR spectra were recorded at 121 MHz using a 
Bruker ACF300 spectrometer with external automatic 
referencing. 
   13C NMR spectra were recorded at 75 MHz using a Bruker 
ACF300 spectrometer. Chemical shifts are quoted in ppm 
relative to tetramethylsilane, the solvent peak being used for 
referencing. Coupling constants are quoted to the nearest 1 
Hz with peak multiplicities being labelled using (where 
appropriate) the abbreviation: d, doublet. 
   Mass spectra were recorded by the EPSRC National Mass 
Spectrometry Service Centre, Swansea, UK, in positive ion 
electrospray (ES+) mode. 
   Analytical thin layer chromatography was carried out 
using Merck Kieselgel 60 F254, coated on aluminium plates, 
with visualisation of spots by quenching of u.v. (254 nm) 
fluorescence or staining with alkaline potassium 
permanganate solution as appropriate. Silica gel with 
particle size 40-63 µm was used for flash chromatography. 
Solvents and reagents were used as supplied commercially 
by SigmaAldrich and Fisher Scientific without additional 
purification. 
    A Büchi R110 Rotovapor was used for the removal of 
solvents under reduced pressure (ca 15 mmHg). 
 
3.2  (10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5-
yl)phenoxy)decyl)triphenylphosphonium bromide 
(AP39) 3 
 
A solution of 10-bromodecanoic acid 5 (500 mg, 1.99 mmol) in 
acetonitrile (5 cm3) was added to a stirred solution of 
triphenylphosphine (522 mg, 1.99 mmol) in acetonitrile (5 cm3) 
and the resulting mixture was heated at reflux for 70 h.23 After 
cooling to room temperature and evaporation of the solvent in 
vacuo, the residue was triturated with toluene (2 x 10 cm3) and  
dissolved in dichloromethane (30 cm3). 5-(4-Hydroxyphenyl)-
3H-1,2-dithiole-3-thione23,24 2 (456 mg, 2.02 mmol), N,N-
dicyclohexylcarbodiimide (431 mg, 2.09 mmol) and 4-
dimethylaminopyridine (12 mg, 0.10 mmol) were added and the 
resulting solution was stirred at room temperature for 22 h 
before filtering through a cotton wool plug and evaporation of 
the filtrate in vacuo. A dichloromethane solution of the residue 
was loaded onto a silica gel flash chromatography column, 
which was subsequently eluted with ethyl acetate, followed by 
methanol. The methanol fractions were combined and 
evaporated in vacuo and a dichloromethane solution of the 
residue was filtered through a filter paper to remove residual 
silica gel before evaporation in vacuo to give the title 
compound 3 (1.05 g, 73%) as a crisp, orange foam (Found [M-
Br]+ (ES+) 641.1766, C37H38O2PS3 requires 
641.1766); νmax(KBr disc)/cm
-1 2925 (m), 2852 (m), 1754 (m) 
(C=O), 1599 (w), 1521 (w), 1485 (s), 1437 (s), 1410 (m), 1317 
(m), 1278 (m), 1185 (s), 1168 (s), 1112 (s), 1026 (s), 996 (m), 
896 (w), 839 (w), 747 (m), 722 (m), 690 (m), 535 (m) and 508 
(m); 1H NMR (300 MHz, CDCl3) 7.95-7.65 (17H, m, aryl 
C(2)H, aryl C(6)H and phenyl CH), 7.42 (1H, s, CHC=S), 7.23 
(2H, part of AA'BB', J = 8.5 Hz, aryl C(3)H and C(5)H), 3.85 
(2H, m, CH2P
+), 2.58 (2H, t, J = 7.5 Hz, CH2C=O), 1.80-1.55 
(6H, m, 3 x CH2) and 1.42-1.19 (8H, m, 4 x CH2); 
31P NMR 
(121 MHz, CDCl3) 25.7 (P
+); 13C NMR (75 MHz, CDCl3) 
214.9 (C=S), 183.7 (CH=C-S), 171.7 (C=O), 153.6 (arylC-O), 
135.8 (arylC-C=CH), 134.9 (phenylC-H), 133.6 (d, J = 9 Hz, 
phenylC-H), 130.4 (d, J = 13 Hz, phenylC-H), 128.9 (C=CH-
C(S)), 128.1 (arylC-H), 122.9 (arylC-H), 118.3 (d, J = 83 Hz, 
phenylC-P+), 34.2 (CH2C(O)), 30.3 (d, J = 13 Hz, CH2), 29.0 
(CH2), 28.9 (2 x CH2), 28.8 (CH2), 24.6 (CH2), 23.0 (CH2) and 
22.5 (d, J = 18 Hz, CH2P
+).  
     
 
3.4 Morpholin-4-ium-4 methoxyphenyl(morpholino) 
phospinodithioate (GYY4137)  
 
GYY4137 was synthesised as previously described14. 
3.5  Cell Culture 
Human cerebral microvascular endothelial cells 
(hCMEC/D3) were isolated from human brain and kindly 
provided by Dr. Pierre-Olivier Couraud, University of Paris 
Descartes34-36. The bEND.3 mouse microvascular 
endothelial cell line was purchased from the American Type 
Culture Collection, (ATTC #CRL-2299, Manassas, VA)37,38. 
 The vascular endothelium is a prime target for oxidative 
stress in vivo and loss of endothelial function and cell death 
are observed in cardiovascular diseases such as 
atherosclerosis, hypertension and diabetes39,40. Therefore we  
used these cells as an in vitro model of cellular oxidative 
stress. 
 hCMEC/D3 cells were seeded on type I collagen (Sigma, 
rat tail; dilution 1:30) and cultured in endothelial cell media 
MV2 (PromoCell; C-22221) with a supplement mix 
(PromoCell; C-39226) diluted to give fetal bovine serum 
(2.5%), epidermal growth factor (1.25 ng/ml), basic 
fibroblast growth factor (2.5 ng/ml), insulin-like growth 
factor (5 ng/ml), vascular endothelial growth factor 165 
(0.125 ng/ml), ascorbate (0.25 µg/ml) and hydrocortisone 
(0.05 ng/ml). hCMEC/D3 cells constitutively express 
microvascular endothelial cell makers including von 
Willebrand factor, CD31 (PECAM-1) and CD105 (endoglin) 
up to passage 35. Cells used in this current study were 
between passages 25-34. The commercial bEND.3 mouse 
microvascular endothelial cell line was cultured as 
described37,38. Murine bEnd.3 cells were maintained in 
DMEM containing glucose (1g/l) supplemented with 10% 
fetal bovine serum (10%), non-essential amino acids, (1%) 
penicillin (100 IU/ml) and streptomycin (100 µg/ml) at 37 
°C in 10% CO2.   
 
 
 
3.6  Detection of hydrogen sulfide in living 
endothelial cells 
 
Cells were seeded in Lab-Tek II chamber coverglass 
(Nalgen Nunc International) and incubated overnight at 
37oC and 10% CO2 humidified incubator. After attachment, 
the cells were loaded with 7-azido-4-methylcoumarin 
(AzMC, SIGMA L511455)30,31 and MitoTracker Red 
CMXRos (Invitrogen M7512) fluorogenic dyes at 10 
microM and 50 nM final concentration, respectively, for 30 
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min. Next, 100 nM of AP39 3 was added with fresh media 
and cells were further incubated for 1 hour, washed twice 
with PBS containing calcium and magnesium. 50 µl of PBS 
was then added to each chamber and micro cover glass was 
attached. The dye’s specific fluorescence was visualized 
under 40x magnification using Nikon eclipse 80i inverted 
microscope with Photometric CoolSNAP HQ2 camera and 
NIS-Elements BR 3.10 software. An additional sulfide-
specific fluorophore, WSP-1 (Caymen, 11179-5)29,30 was 
used to determine intracellular generation of H2S. In these 
experiments, cells were seeded overnight in black 96 well 
microplates (Nalgen Nunc International) and incubated at 
37oC with 10 µM WSP-1 for 30 min30. After this time, cells 
were washed with pre-warmed phenol-red free culture 
media and AP39 (10 nM – 250 nM) added and WSP-1 
fluorescence determined (Ex465nm, Em515nm) using Molecular 
Devices M2e microplate reader.  
 
3.7  Cytotoxicity assays 
To induce oxidative stress, hCMEC/D3 cells were exposed 
to either H2O2 (100 µM), SIN-1 (500 µM) or the lipid 
aldehyde product of lipid peroxidation in vivo, 4-
hydroxynonenal (4-HNE; 10 µM) for 24 hours in the 
presence or absence of H2S donors GYY4137 1 (100 µM), 
AP39 3 (100 nM), ADT-OH 2 (100 nM) or compound 4 (100 
nM). After this time cell viability, as an end point for 
cytotoxicity, was assessed by alamarBlue® assay (AbD 
Serotec; #BUF012) according to the manufacturer’s 
instructions. Fluorescence was then determined using a 
Molecular Devices M2e plate reader (fluorescence; Ex540nm / 
Em612nm) as described. Data are expressed as % of untreated 
or vehicle treated cells (% viability). 
 
3.8  Assessment of mitochondrial membrane 
potential (∆ψm) 
Mitochondrial membrane potential, (∆Ψm) in whole 
hCMEC/D3 cells were measured by using the fluorescent 
potentiometric probe tetramethylrhodamine methyl ester 
(TMRM; Invitrogen). TMRM is a membrane-permeable 
cationic fluorophore that electrophoretically accumulates in 
mitochondria in response to their negative potential and 
decrease of TMRM fluorescence is indicative of ∆Ψm 
disruption and mitochondrial and cellular toxicity. Cells were 
incubated with SIN-1 (500 µM), H2O2 (100 µM) or 4-HNE (10 
µM) in the presence or absence of H2S donors for 18 h and after 
this time, cells were incubated for 30 min with TMRM (200 
nM), washed with warm (37 oC) phosphate buffered saline (pH 
7.4) and TMRM fluorescence (Relative Fluorescence Units; 
RFU) determined by fluorimetry (Ex548nm / Em573nm)
41,42. 
3.9  ATP determination 
hCMEC/D3 cells were seeded overnight on 24 well plates 
(Greiner) containing 1.0 ml culture media and treated with the 
respiratory chain inhibitor rotenone (5 µM), and the oxidants 
SIN-1 (500 µM), H2O2 (100 µM) or 4-HNE (10 µM) in the 
presence or absence of AP39 (100 nM) or GYY4137 (100 µM) 
for 18 hours. After this time, cells were washed twice with ice 
cold phosphate buffered saline (PBS) and lysed with 100 µl of 
ice- cold trichloroacetic acid (TCA; 10% w/v). 5 µl of TCA 
lysate was then added to 200 µl of arsenite buffer (containing 
80 mM MgSO4, 10 mM KH2PO4 and 100 mM Na2HAsO4, 
mixed in a 1:1:1 ratio; pH 7.4) followed by 10 µl firefly lantern 
extract (containing luciferase; Sigma)41,42. Emitted light was  
recorded on a GloMax Jr, (Promega) luminescence detector as 
described. ATP concentrations were determined using a freshly 
prepared standard curve and samples normalised to cellular 
protein content using a commercial bicinchoninic acid-based kit 
(Bio-Rad). 
3.10  Intracellular oxidant production 
hCMEC/D3 cells were treated with oxidants and H2S donors 
(GYY4137 1 100 µM; AP39 3, 100 nM) as described above 
and the production of mitochondria-derived generation of 
reactive oxygen species were determined by fluorimetry using 
the mitochondria-targeted oxidant probe MitoSox redTM 
(Invitrogen, 5 µM) and fluorescence determined (RFU) Ex390 / 
Em580nm
43. 
3.11  Statistical analysis 
All graphs are plotted with mean ± SEM. In all cases, the mean 
values were calculated from data taken from at least six 
separate experiments, performed on separate days using freshly 
prepared reagents. Where significance testing was performed, 
an independent t-test (Student’s; two populations) was used;     
* P < 0.1, **P < 0.05, ***P < 0.01.  
4  Discussion 
 
H2S has been proposed as novel cytoprotective mediator
22,44-46. 
In isolated mesenchymal progenitor cells RNAi-mediated 
knockdown of CSE potentiated SIN-1, H2O2 and 4-HNE-
mediated mitochondrial toxicity, an effect reversed with 
GYY413722. Genetic knockout of CSE renders endothelial6 and 
striatal Q11147 cells more sensitive to oxidative stress-induced 
toxicity and blood vessels more prone to atherosclerosis21. 
However, it should be noted that this is not seen in all models. 
For example, hepatocytes from CSE-/- mice exposed to galac-
tosamine/lipopolysaccharide were shown to be more sensitive 
to oxidative injury than wild type animals48, although it is un-
clear if the effects were mediated by H2S since CSE knock out 
did not significantly decrease plasma or liver H2S levels and 
markedly increased plasma homocysteine levels48. Neverthe-
less, in cell culture experiments, H2S / HS
- generated from 
NaSH (albeit at ≥ 100 µM) has been shown to prevent detri-
mental cytotoxic effects and oxidative protein modification 
induced by oxidants such as hydrogen peroxide, superoxide, 
hypochlorite and peroxynitrite (reviewed in reference46).  In 
neuronal cells, NaSH (≥ 100 µM) also inhibited oxidative 
stress-mediated cell death after treatment with β-amyloid49 or 
the mitochondrial toxin 1-methyl-4-phenylpyridinium 
(MPP+)50. Furthermore, H2S is also reported to inhibit the ex-
pression and activity of NAD(P)H oxidase, a key source of 
extra-mitochondrial oxidant species51 and it upregulates the 
expression of the antioxidant enzyme thioredoxin-1 in vascular 
endothelial cells52. However, in each of these studies, the con-
centrations of H2S required for each of these studies are often 
vastly excessive (typically >1-200 µM) and well beyond that 
seen in health or extreme pathology. Although the absolute 
level of free H2S gas in the vasculature is not known, the most 
recent analytical techniques have suggested levels of free H2S 
are in the nM to low µM range, suggesting that many of the 
above cellular studies using NaSH or Na2S may not reflect the 
endogenous effects of physiologically relevant concentrations 
of H2S found in the vasculature
2. 
      We recently showed RNAi-mediated knockdown of CSE 
rendered mitochondria more sensitive to oxidative stress- 
induced mitochondrial toxicity, an effect which was 
overcome by the H2S donor GYY4137 1 (albeit ≥100 µM) 
suggesting that endogenous H2S may function to preserve 
mitochondrial integrity22. This is supported by in vivo 
studies. For example, in a rodent cardiac ischaemia-
reperfusion model, both Na2S infusion and selective cardiac 
CSE over-expression preserved mitochondrial ultrastructure, 
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preserved ATP generation and respiratory chain function in 
vivo45, possibly via a mitochondrial pathway involving the 
preservation of Bcl-2 signalling, inhibition of Bax, 
upregulation of PKC and opening of mitochondrial KATP-
channels10,52. 
     Collectively, these in vitro and in vivo studies have strongly 
suggested that mitochondria are key regulatory targets for 
endogenous and exogenously applied H2S suggesting that 
compounds which deliver H2S to mitochondria could be 
therapeutically useful. To test this hypothesis in vitro, we 
exposed microvascular endothelial cells to oxidative insult and 
examined cell viability and mitochondrial toxicity after 
oxidative insult using a novel mitochondria-targeted TPP+-
derived dithiolethione (AP39, 3) and a well established but non-
targeted H2S donor molecule GYY4137 1. Concentrations of 
GYY4137 (100 µM) were chosen based on Figure 3D and the 
reported cytoprotective effects reported for this compound in a 
variety of cellular models14-21. In each assay (Fig. 3-5), AP39  3 
significantly inhibited oxidative stress induced toxicity at 
concentrations more than 1,000-fold lower than that of 
GYY4137 (e.g. 100 nM AP39 c.f.  100 µM GYY4137). In 
contrast, incubation of cells with TPP+-decanoate (compound 4) 
which targets mitochondria, but cannot generate H2S or the H2S 
donor moiety ADT-OH alone (e.g. lacking TPP+), did not 
prevent oxidant-induced cell death (Figs. 3A-C). Similarly, 
incubation of cells with compound 4 and ADT-OH  2 together 
also failed to show cytoprotective effects indicating that the 
whole AP39 molecule (e.g. mitochondria-targeted H2S 
delivery) was required for cell preservation (Figs 3A-C). Whilst 
our study clearly shows inhibition of oxidative stress-induced 
cellular toxicity and mitochondrial preservation by AP39, it is 
not possible to determine from these data whether 
mitochondrial protection was the cause or a consequence of 
cytoprotection. Nevertheless, TPP--derivatised H2S donor 
compounds such as AP39 may be useful tools in studying 
mitochondria-H2S interactions.  
    Although further work is required to define the precise bio-
molecular pathways by which AP39 3 prevents cellular injury, 
the pathways for endogenous mitochondrial generation of H2S 
have recently been uncovered5,52-56. The mitochondrial enzyme 
3-MST generates low levels of H2S and 3-MST-derived H2S 
concentrations in the nanomolar range were very recently 
shown to contribute electrons to the Krebs cycle, enhance 
mitochondrial electron transport and bioenergetics5, an effect 
blocked during oxidative stress54 but reversed with exogenous 
H2S
54. Recently, CSE53 and CBS54,55 have been shown to 
translocate from the cytosol in cells to the mitochondrial matrix 
in response to hypoxic and calcium stress, to generate H2S 
within the mitochondria, possibly acting as an electron acceptor 
in the mitochondrial respiratory chain, resulting in increased 
cellular ATP production and cell preservation53-56. It is possible 
that these effects were also mediated by AP39-derived H2S, 
contributing to the overall cytoprotective effects of this 
compound since we observed co-localisation of H2S generation 
with mitochondria (Fig. 2B) preservation of ATP levels (Fig. 
5B) and mitochondrial ∆ψm (Fig. 4A) and decreased 
mitochondrial oxidant production (Figs. 4B & 5A). Therefore, 
it appears that the endogenous enzymes responsible for H2S 
generation are either located within or translocate to the 
mitochondria in response to cellular stress and mitochondria-
derived H2S contributes to overall cellular bioenergetics and 
cellular health. Since mitochondrial production of H2S is 
perturbed by oxidative stress and mitochondrial dysfunction 
and oxidative stress are key pathological events in several 
human disease states (including hypertension, stroke, 
neurodegenerative disease, arthritis, hepatitis etc; reviewed in1-
3), it is likely that mitochondrial H2S delivery may represent a 
novel approach to study mitochondrial function in health and 
disease and potentially reveals a novel therapeutic strategy to 
treat (or limit) mitochondrial dysfunction in human disease. 
5  Conclusions 
 
Our current study shows that coupling H2S generating 
diothiolethione (AP39) to a moiety well characterised to 
enable selective targeting of intracellular mitochondria 
(TPP+) greatly increased the cytoprotective potency of H2S 
relative to a standard and non-targeted H2S donor compound 
GYY4137. Selective pharmacological manipulation of 
mitochondrial H2S may represent a novel approach to 
preserve mitochondrial function and prevent oxidative 
stress-induced cellular injury in vivo. 
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